Clinical trial · Observational
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) With a Focus on Patients Treated With Rydapt (Midostaurin) in Helsinki and Uusimaa Hospital District
NCT05488613CI-TRIAL-00062022completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS). Real-world health care resource utilization (HCRU) of AML patients was characterized.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Midostaurin | Drug | Midostaurin | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Midostaurin
- description
- Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
- interventionNames
- Drug: Midostaurin
Primary outcomes (1)
- measure
- Number of patients initiating midostaurin treatment
- timeFrame
- throughout the study, approximately 5 years
- description
- Number of patients initiating midostaurin treatment were reported.
Secondary outcomes (7)
- measure
- Number of patients who received Midostaurin at induction and consolidation phases
- timeFrame
- throughout the study, approximately 5 years
- description
- Number of patients who received Midostaurin at induction and consolidation phases were reported.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are diagnosed with acute myeloid leukemia (ICD-10 C92.0) during 1.1.2016-30.6.2020 * Adult (18 years or older) at the time of first diagnosis * Health registry data is available and accessible * Resident in the hospital district HUS at the time of index diagnosis Exclusion Criteria: \- AML patients with no treatment information
References
Publications (0)
Data not yet available
No reference posted for this study.